Abstract: The use of biologics has been a major advance in the treatment of rheumatoid arthritis over the last decade. However, their need for a parenteral route of administration has made them less desirable for some patients. Efforts have been channelled into the development of oral tyrosine kinase inhibitors, and their results have been promising. This article will provide an overall review of three main tyrosine kinase inhibitors which have been studied for patients with rheumatoid arthritis.

Keywords: Janus kinase, mitogen-activated protein kinase, protein kinase inhibitor, rheumatoid arthritis, spleen tyrosine kinase